These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 32880650

  • 1. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
    Tatar M, Keeshin SW, Mailliard M, Wilson FA.
    JAMA Netw Open; 2020 Sep 01; 3(9):e2015756. PubMed ID: 32880650
    [Abstract] [Full Text] [Related]

  • 2. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH, Ward JW, Sherman KE.
    Clin Gastroenterol Hepatol; 2019 Apr 01; 17(5):930-939.e9. PubMed ID: 30201597
    [Abstract] [Full Text] [Related]

  • 3. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT.
    BMC Infect Dis; 2019 Dec 02; 19(1):1019. PubMed ID: 31791253
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME.
    J Gastroenterol Hepatol; 2016 Apr 02; 31(4):872-82. PubMed ID: 26514998
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z, Mafirakureva N, Stone J, Keevans M, Betts-Symonds G, Crowley D, McHugh T, Avramovic G, Lambert JS, Vickerman P.
    Int J Drug Policy; 2021 Oct 02; 96():103394. PubMed ID: 34412938
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.
    JAMA; 2003 Jul 09; 290(2):228-37. PubMed ID: 12851278
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
    Lim AG, Aas CF, Çağlar ES, Vold JH, Fadnes LT, Vickerman P, Johansson KA.
    Addiction; 2023 Dec 09; 118(12):2424-2439. PubMed ID: 37515462
    [Abstract] [Full Text] [Related]

  • 8. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.
    Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP.
    Clin Infect Dis; 2018 Jan 18; 66(3):376-384. PubMed ID: 29020317
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.
    Chugh Y, Premkumar M, Grover GS, Dhiman RK, Teerawattananon Y, Prinja S.
    BMJ Open; 2021 Feb 15; 11(2):e042280. PubMed ID: 33589457
    [Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T, Dumont IP, Heinzow HS, Hutton DW.
    Gastroenterology; 2017 Dec 15; 153(6):1531-1543.e2. PubMed ID: 29074450
    [Abstract] [Full Text] [Related]

  • 11. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y.
    J Hepatol; 2018 Oct 15; 69(4):785-792. PubMed ID: 30227916
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA, Chung W, Choi HY, Ki M, Jang ES, Jeong SH.
    Liver Int; 2019 Jan 15; 39(1):60-69. PubMed ID: 29998565
    [Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.
    Health Technol Assess; 2006 Sep 15; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [Abstract] [Full Text] [Related]

  • 14. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
    Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM.
    Ann Intern Med; 2012 Feb 21; 156(4):263-70. PubMed ID: 22056542
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
    Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP.
    Int J Drug Policy; 2019 Oct 21; 72():160-168. PubMed ID: 31085063
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.